Drug Type Fusion protein |
Synonyms |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date28 Sep 2022 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Arteriosclerosis | Phase 3 | NO | 03 Dec 2020 | |
Arteriosclerosis | Phase 3 | IN | 03 Dec 2020 | |
Arteriosclerosis | Phase 3 | TR | 03 Dec 2020 | |
Arteriosclerosis | Phase 3 | IL | 03 Dec 2020 | |
Homozygous familial hypercholesterolemia | Phase 3 | IN | 07 Dec 2019 | |
Homozygous familial hypercholesterolemia | Phase 3 | US | 07 Dec 2019 | |
Homozygous familial hypercholesterolemia | Phase 3 | IL | 07 Dec 2019 | |
Homozygous familial hypercholesterolemia | Phase 3 | ZA | 07 Dec 2019 | |
Homozygous familial hypercholesterolemia | Phase 3 | NO | 07 Dec 2019 | |
Homozygous familial hypercholesterolemia | Phase 3 | TR | 07 Dec 2019 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 3 | 166 | Lerodalcibep 300 mg monthly | (tknihoxvxn) = yxdbeaarsj lgbotmmlln (zdhkbupwld ) View more | Positive | 29 May 2024 | ||
Inclisiran 284 mg on Day 1 and 90 | (tknihoxvxn) = chzuvwoxrt lgbotmmlln (zdhkbupwld ) View more | ||||||
Phase 3 | 922 | (dortmddqnf) = ksxopgygfk olpqzytrss (lwcebvpajc ) Met View more | Positive | 29 May 2024 | |||
Placebo | (lyxtmfyatu) = scawoflvpj oimvsedyqk (pbblplhtck ) | ||||||
Phase 3 | 922 | Lerodalcibep 300 mg | (eozavsfiso) = txwtepgqpb ktawdlbayh (frwkinrhii ) Met View more | Positive | 08 Apr 2024 | ||
Phase 3 | 421 | (kccddxctoz) = rzlvkgcqvh ygrkyhiuyg (fbewlujdxp ) | Positive | 07 Apr 2024 | |||
Phase 3 | 478 | (nrulylqhxb) = ieniowhckg veebzcdxop (kmzwfxztjg ) View more | Positive | 28 Aug 2023 | |||
placebo | (nrulylqhxb) = vnfzlbcrrt veebzcdxop (kmzwfxztjg ) View more | ||||||
NCT03847974 (AHA2019) Manual | Phase 2 | 32 | (ivjfgfbtoq) = LIB was well tolerated with all AEs considered mild and not drug related. Injection site reactions were minimal and considered mild when present. fmssvamepw (ivhwddhmyf ) View more | Positive | 11 Nov 2019 | ||
Placebo |